Understanding Host–Phage Interactions in Chronic Wounds, Emphasising Inflammatory Markers and Neutralising Antibody Responses
Verständnis von Wirt-Phagen-Interaktionen bei chronischen Wunden mit Fokus auf inflammatorische Marker und neutralisierende Antikörperantworten
The International Journal of Lower Extremity Wounds · 03.11.2026
DOI: 10.1177/15347346261501752 ↗Auf einen Blick
Bei 100 Patient:innen mit chronischen Wunden war die Behandlungsdauer unter Bakteriophagen-Therapie kürzer als unter konventioneller Therapie. Entzündungsmarker sanken in beiden Gruppen; neutralisierende Antikörper traten selten auf.
Fragestellung
Welche Effekte hat Bakteriophagen-Therapie bei chronischen Wunden auf Entzündungsmarker, neutralisierende Antikörper und die Wundheilung?
Methode
Prospektive, interventionelle, nicht randomisierte Kontrollstudie; 100 Patient:innen mit chronischen Wunden (>6 Wochen); 50 erhielten Bakteriophagen-Therapie, 50 konventionelle Therapie; Serumwerte an drei Zeitpunkten per ELISA.
Ergebnisse
Die Therapiedauer war in der BT-Gruppe kürzer als in der CT-Gruppe (1,46 ± 0,63 Monate vs. 2,92 ± 1,02 Monate; P < .001). IL-1β, IL-6, MMP-9 und TGF-β nahmen in beiden Gruppen signifikant ab. Neutralisierende Antikörper: 2/45 (4,4 %) in der BT-Gruppe.
Schlussfolgerung der Autor:innen
BT förderte eine schnellere Wundheilung, ohne das Zytokinprofil deutlich zu verändern. Etwa 4,4 % entwickelten neutralisierende Antikörper, die die Heilung nicht beeinträchtigten, was für eine sichere Anwendung spricht.
Kernaussagen
- BT verkürzte die Therapiedauer gegenüber konventioneller Therapie
- IL-1β, IL-6, MMP-9 und TGF-β sanken in beiden Gruppen
- Neutralisierende Antikörper wurden bei 2/45 BT-Patient:innen nachgewiesen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Lower Extremity Wounds, online erschienen am 03.11.2026. Verfasst von Aman Kumar Chandel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Die Arbeit nennt 14 Literaturangaben.
Themen: Wundversorgung
Abstract (Originalsprache)
Background
Chronic wounds cause considerable morbidity, which is further compounded by antimicrobial resistance and biofilm formation. Bacteriophage therapy (BT) presents a promising alternative. However, issues such as host immune neutralisation and inflammatory reactions remain unresolved.
Methods
This prospective, interventional, non–randomized control study was conducted at the Institute of Medical Sciences, Banaras Hindu University, from July 2022 to February 2026. It involved 100 patients with chronic wounds (>6 weeks). It had two groups: Group I (n = 50) received bacteriophage therapy (BT), while Group II (n = 50) received conventional therapy (CT). Bacteriophages were isolated and applied topically every other day. Serum levels of IL-1β, IL-6, MMP-9, and TGF-β were measured using ELISA at baseline, immediately after therapy, and at six weeks after treatment completion. Neutralising antibodies in the BT group were measured through serum–phage interaction assays and data analysis was done.
Results
Follow-up was completed in 90% of patients. Diabetes (50%) was the most common comorbidity. The most commonly isolated bacteria were Pseudomonas aeruginosa (30%), Escherichia coli (26%), and Klebsiella pneumoniae (26%). The therapy duration was significantly shorter ( P < .001) in the BT group (1.46 ± 0.63 months) than in the CT group (2.92 ± 1.02 months). Levels of IL-1β, IL-6, MMP-9, and TGF-β decreased significantly in both groups during and after treatment. Neutralising antibodies were detected in only 2 out of 45 BT patients (4.4%) with complete follow-up.
Conclusion
BT promoted faster wound healing without notably altering cytokine profiles. The fact that around 4.4% of patients developed neutralising antibodies, which did not interfere with healing, suggests that phage therapy can be safely applied.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
- Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
- Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
ORCID-Profile: Aman Kumar Chandel, Sangeeta Kumari, Gopal Nath, Satyanam Kumar Bhartiya
Zitieren
APA
Chandel, A. K., Kumari, S., Nath, G., Mishra, S. P., & Bhartiya, S. K. (2026). Understanding Host–Phage Interactions in Chronic Wounds, Emphasising Inflammatory Markers and Neutralising Antibody Responses. The International Journal of Lower Extremity Wounds. https://doi.org/10.1177/15347346261501752
Vancouver
Chandel AK, Kumari S, Nath G, Mishra SP, Bhartiya SK. Understanding Host–Phage Interactions in Chronic Wounds, Emphasising Inflammatory Markers and Neutralising Antibody Responses. The International Journal of Lower Extremity Wounds. 2026. doi:10.1177/15347346261501752
BibTeX
@article{Chandel2026,
author = {Chandel, Aman Kumar and Kumari, Sangeeta and Nath, Gopal and Mishra, Surendra Pratap and Bhartiya, Satyanam Kumar},
title = {Understanding Host–Phage Interactions in Chronic Wounds, Emphasising Inflammatory Markers and Neutralising Antibody Responses},
journal = {The International Journal of Lower Extremity Wounds},
year = {2026},
doi = {10.1177/15347346261501752}
}
EUVIMED